Leveraging TNFR2 for antitumour immunity: T reg depletion and myeloid reprogramming versus T cell costimulation
Linda Mårtensson, Petra Holmkvist, Kirstie L.S. Cleary, Carolin Svensson, Monika Semmrich, Niyaz Yoosuf, Alexandra Gabriela Ferreira, Mathilda Kovacek, Mimoza Bodén, Therese Blidberg, Osman Dadas, Jenny Mattsson, David Ermert, Elin Birgersson, Vicentiu Andrei Pitic, , Ingrid Teige
This paper evaluates two TNFR2-targeting antibodies, showing ligand-blocking antibodies deplete T regs and reprogram myeloid cells, while agonists directly co-stimulate T and NK cells, both leading to anti-tumor effects.
Cancer Research · Jul 17, 2026Peer-reviewedImmunology